Sonnet BioTherapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Current	$ 55,486us-gaap_CurrentForeignTaxExpenseBenefit		$ 40,935us-gaap_CurrentForeignTaxExpenseBenefit
Deferred	(267,960)		(167,554)
Current	318us-gaap_CurrentFederalTaxExpenseBenefit
Deferred	(1,266,980)		(652,624)
Current
Deferred	(149,056)		(76,786)
Change in valuation allowance	1,151,691	896,964	896,964
Income tax provision	$ (476,501)us-gaap_IncomeTaxExpenseBenefit		$ 40,935us-gaap_IncomeTaxExpenseBenefit

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.

Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.

Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.